Congestion Continues In Private Label Mucinex Pipeline; Court Rules Against Mutual
This article was originally published in The Tan Sheet & The Rose Sheet
A ruling for RB n Pennsylvania federal court comes as it girds for increased competition from additional guaifenesin expectorant formulations that are the equivalents of Mucinex brand products and that Perrigo is marketing under license from manufacturer Allergan.
You may also be interested in...
Mutual Alleges Mucinex Monopoly In Extended-Release Guaifenesin
Mutual Pharmaceutical alleges in an antitrust suit that RB attempts to monopolize the extended-release guaifenesin OTC category with its Mucinex product. The suit says Mutual has lost “tens of millions” due to RB's failure to honor a contract to supply an “authorized generic” of the product.
Monetary Relief Slim From Dietary Supplement Multi-level Marketer Operating Pyramid Scheme
Federal judge found for FTC on all counts in its complaint against defendants linked to MLM selling Success By Health supplements through affiliates, or independent sales associates. But damages limited to $6,829 for five instances of rejecting consumer requests for refunds after shipping delay.
Claritin Liqui-Gels' Label ‘Refresh’ Loses Blue Sky
Changes replace blue background used across Claritin line with white above navy blue waves. Brand’s still printed in white text, but in letters with blue shadow; other package-front text is in red or green instead of yellow.